Company: CRL
Filing Date: 2025-04-02
Form Type: DEF 14A
Source: 0001104659-25-030908
Chunk: 22

Company: CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Filing Date: 2025-04-02
Form: DEF 14A
Chunk 22
---
, and is responsible for reviewing, evaluating, and advising the Board and Company management regarding: • the Company’s impact on responsible animal utilization, including the Company’s progress in developing, investing in and/or acquiring the scientific and technological resources and expertise required to appropriately reduce the impact of animals in Company operations; • the Company’s efforts to ensure effective governance and oversight of responsible animal utilization practices and operating standards of care; and • the Company’s stakeholder messaging on these matters. Science and Technology Committee The Science and Technology Committee met three times during 2024. The current members of the Science and Technology Committee are: Drs. Andrews (Chair), Kochevar, Mackay and Thompson, and Mr. Llado. The Science and Technology Committee is responsible for: • identifying and discussing significant emerging trends and issues in research and development and science and technology; • reviewing, evaluating, and advising the board regarding our technology and scientific programs and initiatives; • reviewing, evaluating, and advising the Board on progress in developing and/or acquiring the scientific and technological resources and expertise required to achieve our long-term strategic goals and objectives; • reviewing and making recommendations to the Board on our internal and external investments in science and technology; • reviewing our approaches to acquiring and/or gaining access to a range of distinct science and technology resources; and • reviewing, evaluating, and advising the Board regarding the Company’s assessment of the risks and benefits associated with technologies in which we are currently or potentially investing, or those that represent a significant portion of our research and development efforts. Strategic Planning and Capital Allocation Committee The Strategic Planning and Capital Allocation Committee met five times during 2024. The current members of the Strategic Planning and Capital Allocation Committee are: Messrs. Bertolini (Chair), Foster, Wallman, Dr. Thompson, and Ms. Kemps-Polanco. The Strategic Planning and Capital Allocation 22 Committee is responsible for reviewing our capital structure, financial strategies, major acquisitions and investment policies to support prudent and effective capital allocation. The Strategic Planning and Capital Allocation Committee is responsible for review of: • matters pertaining to our portfolio of business; • major acquisitions and capital investment projects; • our capital structure and material financial strategies; • our derivatives and hedging strategies (in coordination with the Audit Committee); • our investment policies and practices, including requirements for major acquisitions and divestitures, collaborations and joint ventures; • matters pertaining to our long-term business objectives and strategic plan development, including making recommendations for the Board for approval; and • our dividend and share repurchase policies and programs